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Reply to ‘‘Biliary atresia: Does ethnicity matter?’’
To the Editor:
We welcome the comment of Girard et al. [1] to our systematic
review on the epidemiology of primary sclerosing cholangitis
(PSC) and primary biliary cirrhosis (PBC) [2]. The authors under-
score the need for proper assessment of ethnicity in epidemiolog-
ical studies of rare diseases such as biliary atresia, PSC, and PBC.
The apparent familial risk, albeit with a low absolute risk,
together with the reported genetic risk loci, point in the direction
of a complex genetic predisposition belying both PSC and PBC.
Recently, disparate associations with several genetic risk loci
have been reported in PSC patients from various ethnic back-
grounds [3]. For PBC, little is known about ethnic differences
since the majority of studies have been performed with Cauca-
sian patients. Notably, a large multicenter study in the US was
performed comparing PBC patients with geographically and eth-
nically diverse backgrounds [4]. The authors showed more severe
disease in African Americans and Hispanics compared to Cauca-
sians. In addition, for inﬂammatory bowel disease, which is clo-
sely associated with PSC, it has been well documented that
incidence rates in 2nd generation immigrants with a different
ethnic background assume the same levels as those for the indig-
enous population, pointing towards environmental factors [5–7].
For PSC, population-based trends in incidence and prevalence
rates with regard to ethnic background are lacking. One study
from Southern Israel reported higher prevalence rates for PBC
among Jews and immigrants compared to Arabs and native Israe-
lis and in a study from Southeast Asia, the prevalence rate in the
Chinese population was almost twice as high as in the Malay pop-
ulation, though the small number of included patients is a limita-
tion of both studies. [8,9] The data presented by Girard et al. [1]
exemplify our conclusion that large true population-based epide-
miological studies with meticulous case-ﬁnding, case-ascertain-
ment, as well as detailed phenotyping (including ancestry) are
needed to provide clues for unraveling genetic and environmen-
tal risk factors for these diseases.
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Statin hepatotoxicity and the dilemma of causality in rare
hepatic adverse drug reactions
To the Editor:
In his editorial, Bader [1] highlights the problems associated with
assessing statin-induced hepatotoxicity, a rare hepatic adverse
drug reaction (ADR). However, the deﬁnitions of hepatotoxicity
and idiosyncratic reactions are used by Bader in a confusing
way. With the appraisal ‘‘Yes! Statins can be given to liver
patients’’ Bader also creates the impression that statins are
withheld from patients with liver disease [1]. At least outside
the US, however, mainstream physicians including hepatologists
never had a problem prescribing statins to their liver patients;
uncertainty exists only how to proceed in cases of decompen-
sated liver cirrhosis.
Björnsson et al. [2] have clearly shown that statins can cause
idiosyncratic hepatotoxicity. In general, drug hepatotoxicity
refers to either of two different underlying reactions, namely
the dose dependent, predictable, and hence intrinsic reaction,
or the dose independent, unpredictable, and hence idiosyncratic
one. Limiting ‘‘hepatotoxicity’’ to the dose dependent reaction
leaves the reader with the impression that statins are not hepa-
totoxic due to lack of dose dependency [1]; on the contrary, statin
Letters to the Editor702 Journal of Hepatology 2012 vol. 57 j 699–711
